A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

147 sites for NCT04293562

BCR-ABL1 Fusion, +48 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation, +12 more drugs

cellular therapy, +4 more types

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

198 sites for NCT04102020

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

48 sites for NCT02416388

BCR-ABL1 Fusion, +24 more biomarkers

Acute Myeloid Leukemia

cyclosporine, +5 more drugs

chemotherapy, +1 more type

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

14 sites for NCT04571645

ASXL1 Loss, +27 more biomarkers

Acute Myeloid Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

1 site for NCT04797767

ASXL1 Loss, +23 more biomarkers

Acute Biphenotypic Leukemia, +2 more conditions

cladribine, +4 more drugs

chemotherapy, +1 more type

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

1 site for NCT04990323

ASXL1 Loss, +23 more biomarkers

Acute Myeloid Leukemia, +4 more conditions

ECT-001 expanded cord blood

cellular therapy

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT

1 site for NCT04959903

ABL1 Fusion, +69 more biomarkers

Acute Lymphoblastic Leukemia, +1 more condition

allogeneic hematopoietic stem cell transplantation

cellular therapy

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

22 sites for NCT04232241

ASXL1 Loss, +31 more biomarkers

Acute Lymphoblastic Leukemia, +2 more conditions

allogeneic hematopoietic stem cell transplantation

cellular therapy

Optimizing PTCy Dose and Timing

1 site for NCT03983850

ASXL1 Loss, +49 more biomarkers

Acute Myeloid Leukemia, +12 more conditions

busulfan, +4 more drugs

chemotherapy, +1 more type

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

1 site for NCT04817241

ASXL1 Loss, +24 more biomarkers

Acute Myeloid Leukemia

cytarabine, +3 more drugs

chemotherapy

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

10 sites for NCT02649790

ASXL1 Loss, +23 more biomarkers

Acute Myeloid Leukemia, +4 more conditions

abiraterone, +4 more drugs

chemotherapy, +2 more types